Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | F9 | P00740 | 1/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.30 |
| ▸ | ATR | Q13535 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33526112 | 0.92 | LMNA (0.32) | LMNAPOLBMEN1HPGDKMT2A | |
| SCHEMBL33525786 | 0.90 | KRAS (0.34) | LMNAPOLBMEN1HPGDKMT2A | |
| SCHEMBL33526107 | 0.88 | EIF4EBP1 (0.31) | — | |
| SCHEMBL34473403 | 0.88 | LMNA (0.33) | LMNAPOLBMEN1HPGDKMT2A | |
| SCHEMBL26114998 | 0.87 | THRB (0.31) | LMNAPOLBMEN1HPGDKMT2A | |
| SCHEMBL30587224 | 0.87 | THRB (0.31) | LMNAPOLBMEN1HPGDKMT2A | |
| SCHEMBL34473184 | 0.87 | LMNA (0.33) | LMNAPOLBMEN1HPGDKMT2A | |
| SCHEMBL34474104 | 0.85 | LMNA (0.32) | LMNAPOLBMEN1HPGDKMT2A | |
| SCHEMBL34474807 | 0.83 | LMNA (0.32) | LMNAPOLBMEN1HPGDKMT2A | |
| SCHEMBL34473760 | 0.82 | LMNA (0.33) | LMNAPOLBMEN1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600733-B2 | KRAS inhibitors | ELI LILLY AND COMPANY (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260092075-A1 | KRAS INHIBITORS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600733-B2 | KRAS inhibitors | KRAS, NRAS, HRAS | LMNA 2137/4885POLB 1113/4885MEN1 404/4885 |
| US-20260092075-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | LMNA 2418/4885POLB 911/4885MEN1 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.